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Abstract
Background: Previous studies have demonstrated that expression of CD105 is a sensitive marker
and indicator of endothelial cell/microvessel activation and proliferation in aggressive solid tumour
growth and atherosclerotic plaque lesions. Since intimal neovascularization contributes significantly
to subsequent plaque instability, haemorrhage and rupture.
Methods: We have used immunohistochemical analysis to investigate the expression of CD105-
positive vessels in both large (carotid) and medium calibre (coronary and middle cerebral artery,
MCAs) diseased vessels in an attempt to identify any correlation with plaque growth, stage and
complication/type.
Results: Here we show, that carotid arteries expressed intimal neovascularization associated with
CD105-positive endothelial cells, concomitant with increased inflammation in early stage lesions,
preatheroma (I-III) whilst they were not present in coronary plaques of the same grade. Some of
these CD105-positive neovessels were immature, thin walled and without smooth muscle cell
coverage making them more prone to haemorrhage and rupture. In high-grade lesions, neovessel
proliferation was similar in both arterial types and significantly higher numbers of CD105-positive
vasa vasorum were associated with plaque regions in coronary arteries. In contrast, although the
MCAs exhibited expanded intimas and established plaques, there were very few CD105 positive
neovessels.
Conclusion: Our results show that CD105 is a useful marker of angiogenesis within adventitial
and intimal vessels and suggest the existence of significant differences in the pathological
development of atherosclerosis in separate vascular beds which may have important consequences
when considering management and treatment of this disease.
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Background
Atherosclerosis is strongly associated with symptomatic
cardiovascular disease and ischemic stroke, which are the
leading causes of death and disability in the Western
world. Atherosclerosis is considered to be a multifactorial
disease with numerous risk factors including smoking,
alcohol abuse, hypertension, diabetes mellitus, dyslipi-
demia and infection with microorganisms including
Chlamydia pneumoniae [1]. All these factors involve com-
plex interactions between pathways associated with
inflammation, lipid metabolism, coagulation, hypoxia,
apoptosis and the immune response. Atherosclerotic
plaque instability is also an independent risk factor for
ischemic stroke [2-5]. In the absence of atherosclerosis,
normal vessel walls have a microvasculature that is con-
fined to the adventitia and outer media [6]. Intimal neo-
vascularization of human arteries was first noticed and
linked with atherosclerosis and intimal thickening by
Koester in 1876 [7]. As the disease progresses, the intima
thickens and oxygen diffusion is impaired [8]. In athero-
sclerotic plaques angiogenesis allows the formation of
new microvessels to maintain oxygen and nutrient supply
for vascular cells [5]. Neovessel growth occurs in regions
of atherosclerotic lesions undergoing remodelling, plaque
'shoulders' prone to rupture. There is a cellular inflam-
matory response to injury in the early remodelling stage
of repair, in which angiogenesis may also play an
important role. In pathological conditions, neovasculari-
zation varies from a transient contribution to healing to a
permanent contribution for tissue regeneration [9].
A variety of studies, suggest that neovascularization con-
tributes to the growth of atherosclerotic lesions, is associ-
ated with symptomatic carotid disease, and is a key factor
in plaque de-stabilization leading to rupture [10,11].
Some of the neovessels are irregular and immature, simi-
lar to those found in solid tumour vascularization and
therefore may contribute to the development of intra-
plaque haemorrhage and subsequently plaque instability
[5,7-9,12].
CD105 is a homodimeric integral membrane glycopro-
tein composed of disulfide-linked subunits of 90-95 kDa
[13] and is a component of the transforming growth fac-
tor-β receptor complex. CD105 is predominantly
expressed in angiogenic endothelial cells and is up-regu-
lated during hypoxia via the hypoxia-inducible factor-1α
which directly binds to the hypoxia response element in
the CD105 promoter [14,15]. CD105 is a sensitive marker
for identification of tumour neovascularization, growth
and prediction of outcome [16,17]. CD105 is also sensi-
tive marker and much more specific than CD31 or TGF-β1
for assessing neovascularization in atherosclerotic
plaques [18,19], whilst levels of circulating soluble
CD105 can accurately predict the presence of unstable
plaques and even plaque rupture [20].
Here, we visualised CD105-positive vessels to ascertain
the density of neovessels and the different vessel mor-
phology within the neointima's of large vessel (carotid)
and smaller calibre coronary and middle cerebral artery
plaques in order to estimate the role of angiogenesis in
different stages of development of atherosclerotic lesion
from different vascular beds with known histological dif-
ferences.
Methods
Carotid and coronary specimens and anatomo-pathology
We included 38 human carotid arteries with low to mod-
erate stenosis (less than 50% by EcoDoppler imaging,
angio-RM or angio-TAC), 20 MCAs and 32 coronary arter-
ies obtained as vascular transplants from organ donors
and post-mortem autopsies, Table 1. Carotid arteries,
including the common carotid artery, and a large portion
of internal and external carotids were excised by a vascular
surgeon as a part of a standard procedure for organ trans-
plantation. There was no time delay as the other organs
were removed simultaneously. The arteries were removed,
immediately rinsed in sterile 0.9% saline, snap-frozen in
liquid nitrogen and stored at -80°C.
Prior to experimentation the arteries were fixed for 24
hours in buffered formalin, briefly decalcified to remove
excess calcium and embedded in paraffin. Sections (5 μm)
were cut on a microtome. Plaque morphology was evalu-
ated by analysis of haematoxylin-eosin stained serial sec-
tions obtained at intervals of 3 mm. Carotid, coronaries
and MCA plaques were classified according to the Ameri-
can Heart Association (AHA) [21], with some modifica-
tions in the case of carotid arteries because points of
calcification are common in normal carotid arteries. Rep-
resentative sections were used for immunohistochemistry.
The study was approved by the local ethical committee in
accordance with institutional guidelines and the family's
written informed consent was obtained.
Immunohistochemical analysis
Paraffin-processed sections (5 μm) were deparaffinized in
xylene and rehydrated in graded ethanol solutions. Slides
were then rinsed in distilled water and treated with 10%
hydrogen peroxide in methanol (30 minutes at RT) to
remove endogenous peroxidase activity. Sections were
blocked with a 5% of normal serum in PBS-tween 0.1%
(30 minutes at RT). Slides with the arterial specimens
were then incubated with the specified dilution of pri-
mary antibody anti-CD105 (1:50, goat polyclonal anti-
body, R&D Systems, Abingdon, Oxford, UK) or anti-
CD34 (1:50, mouse monoclonal antibody, NovoCastra,
Newcastle, UK) overnight at 4°C. After washing 3 times inJournal of Angiogenesis Research 2009, 1:6 http://www.jangiogenesis.com/content/1/1/6
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PBS, biotinylated secondary antibody (Vector Laborato-
ries) was used at a 1:200 dilution, and incubated at RT for
1 hour. After rinsing in PBS, standard Vectastain (ABC)
avidin-biotin peroxidase complex (Vector Laboratories)
was applied, and the slides were incubated at RT for 30
minutes. Colour was developed using 3, 3'- diaminoben-
zidine (DAB) and sections were counterstained with hae-
matoxylin before dehydration, clearing, and mounting.
Negative controls in which the primary antibody was
replaced with PBS were used to test for non-specific bind-
ing (data not included). All immunostaining was assessed
by 2 investigators simultaneously using a double-headed
light microscope. Results are presented in Tables 2, 3 and
4.
Quantitative analysis
Manual microvessel counting was performed by a single
observer. All neovessels of the neointimal and adventitial
areas were counted using fields at × 200 magnification
with the Olympus Vanox AHBT3 microscope in all type of
arteries. The density of neovessels of the adventitial layer
containing plaque was compared to the non-containing
plaque area. Each microvessel was defined as a lumen sur-
rounded by a layer of endothelial cells highlighted by
immunostaining with anti-CD34 antibody and each
active neovessel was defined as positive with anti-CD105
antibody. The total microvessel count for each sample sec-
tion was divided by the area covered by that section.
Microvessel counts were expressed as microvessels per
square millimetre of plaque sectional area. The morpho-
metric study was performed using a Sony DXC-S500 cam-
era and processing performed using the Visilog 4.1.5
(Noesis) program.
In this study, we compared the number of anti-CD105
and anti-CD34 positive neovessels per square millimetre
in the neointima of selected carotids (n = 4) and coronar-
ies (n = 4) to confirm the selectivity of the antibodies. The
number of microvessesls stained with anti-CD34 anti-
body was higher than anti-CD105 ones in both types of
arteries. Results are presented in Table 2. Thirty eight
carotids, 32 coronaries and 20 MCAs were subsequently
analyzed for the expression of CD105.
Statistical analysis
All statistical analysis was performed with the SPSS for
Windows statistical software program (version 15.0, SPSS
Inc.). One-way ANOVA was used to assess the statistical
significance of patient's clinical data and differences
between the three groups of arteries in relation to quanti-
tative variables. The Chi-Square test was used for measure-
ment of differences in qualitative variables. Differences in
the number of neovessels in the intimas between carotid
and coronary arteries was analysed using the Wilcoxon
non-parametric test. Differences in the number of neoves-
sels per square millimetre in the neointima and the type
of lesion or the maximum thickness of neointima (μm)
were analysed with the Kruskal-Wallis test. Means
between numbers of neovessels in different areas of the
adventitia were compared using the Student-t test. Statis-
tical significance was assumed when P < 0.05.
Table 1: Patient's clinical data
Feature Carotids (n = 38) MCA (n = 20) Coronaries (n = 32) P-value
Age (Mean ± SD) 67 ± 15* 69 ± 15† 52.3 ± 10.8*† 0.000
Sex (/) 25/13 14/6 25/6 NS
WBC × 109/L (Mean ± SD) 12.3 ± 10.0 10.9 ± 6.1 7.6 ± 2.1 NS
Glucose (Mean ± SD) (mmol/l) 6.7 ± 2.0 9,1 ± 5,4† 5.7 ± 0.9† 0.026
Total cholesterol (Mean ± SD) (mmol/l) 3.4 ± 1.0* 4.6 ± 1.7 5.3 ± 2.0* 0.003
HTA n, (%) 15 (39.5) 13 (65) 5 (16.1) 0.001
DM n, (%) 8 (21.1) 6 (30) 4 (12.9) NS
DLP n, (%) 9 (23.7) 6 (30) 15 (48.4) NS
Smoking n, (%) 9 (23.7) 11 (55) 23 (74.2) 0.000
Alcohol abuse n, (%) 8 (21.1) 5 (25) 14 (45.2) NS
CAD n, (%) 8 (22.2) 5 (25) 10 (32.3) NS
Statins n, (%) 5 (20.8) 2 (10) 9 (29) NS
Antiplatelets n, (%) 4 (16.7) 6 (30) 4 (12.9) NS
Rasb n, (%) 9 (37.5) 6 (30) 12 (38.7) NS
MCA, middle cerebral arteries; WBC, white blood cells; HTA, hypertension; DM, diabetes mellitus; DLP, dyslipemia; CAD, coronary artery disease; 
Rasb, renin angiotensin system blockers;
*† Statistic significant between these groups; NS, not significant
Table 2: N° neovessels/mm2 stained with anti-CD105 compared 





Carotids (n = 4) 7.9 ± 5.2 1.6 ± 1.1
Coronaries (n = 4) 8.8 ± 6.6 2.1 ± 1.6
Values are mean ± SDJournal of Angiogenesis Research 2009, 1:6 http://www.jangiogenesis.com/content/1/1/6
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Results
A summary of the patient's basic clinical data, derived
from samples which were obtained before death, is pre-
sented in Table 1. Haematoxylin and eosin sections were
classified using the AHA system as; type I, early lesion; II,
fatty streaks; III, intermediate lesion; IV, atheroma; Va,
fibroatheroma; Vb, calcific lesion; Vc, fibrotic lesion and
VI, complicated lesion [21]. Plaque AHA classification
and phenotype characteristics such as inflammation or
calcification are presented in Additional file 1.
Neointimal plaque vascularity
Of the 38 carotid and 32 coronary arteries, we compared
the number of anti-CD105 and anti-CD34 positive neo-
vessels per square millimetre in the neointima of selected
carotids (n = 4) and coronaries (n = 4). The number of
microvessesls stained with anti-CD34 antibody was
higher than anti-CD105 ones in both types of arteries.
Results are presented in Table 2.
In the 38 carotids, 32 coronaries and 20 MCAs analyzed
for CD105 expression, there was an increase of the maxi-
mum thickness of the neointima (μm) in more advanced
lesions compared with intermediate and/or early lesions
(p < 0.05). There was a significant increase in plaque
microvessel density with increased lesion severity in coro-
nary arterial plaques and in carotid arteries (p < 0.05).
There were significantly more microvessels per square mil-
limetre in both intermediate and advanced lesions com-
pared with early lesions. Results are presented in Table 3.
Few neovessels were observed in the neointima's of inter-
mediate MCAs lesions; however intense expression of
CD105 was seen in the intraluminal endothelial cells in
all lesion types.
Expression of CD105 positive vessels in carotid lesions
Positive CD105 immunostaining was observed in the few
neovessels that there were within and surrounding the lip-
idic core in type III/IV lesions. The majority of neovessels
were circular and regular in shape within the lipidic core
(Figure 1A). However, there were also highly irregular,
multilobular, partially collapsed vessels surrounding the
lipidic core. In fibroatheromatous (Va) lesions there were
more highly irregular, multilobular, partially collapsed
vessels than regular-shaped circular vessels within inflam-
matory areas (Figure 1B). The shape of neovessels sur-
Table 3: N° neovessels/mm2 in the neointima and Maximum thickness of neointima (μm) of different arteries
N° neovessels/mm2 Neointima thickness (μm)
Carotid AHA classification
Early (I-III) n = 21 0.04 ± 0.2 626.2 ± 876.5
Intermediate(IV-Va) n = 17 1.8 ± 2.4 1925.7 ± 882.5
P-value 0.000 0.000
Coronaries AHA classification
Early (I-III) n = 11 0.0 512.6 ± 327.6
Intermediate (IV-Va) n = 11 1.3 ± 1.9 1141.9 ± 458.8
Advanced (Vb-VI) n = 10 5.9 ± 7.4 1561.7 ± 1433.6
P-value 0.000 0.003
MCA
Early (I-III) n = 12 0.0 129.2 ± 176.7
Intermediate (IV-Va) n = 8 0.2 ± 0.4 841.67 ± 455.5
P-value NS 0.001
Values are mean ± SD; MCA, middle cerebral arteries; NS, not significant
Table 4: N° neovessels/mm2 in the adventitia of different arteries






Early (I-III) n = 21 2.9 ± 3.2 2.4 ± 2.4 NS
Intermediate(IV-Va) n = 17 3.0 ± 2.1 2.1 ± 2.2 NS
Coronaries
Early (I-III) n = 11 3.7 ± 4.4 1.7 ± 2.5 NS
Intermediate (IV-Va) n = 11 2.3 ± 1.6 0.8 ± 1.3 0.003
Advanced (Vb-VI) n = 10 3.0 ± 2.8 2.0 ± 1.9 NS
Values are mean ± SD; NS, not significantJournal of Angiogenesis Research 2009, 1:6 http://www.jangiogenesis.com/content/1/1/6
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rounding the lipidic core (Figure 1-D1), within plaque
shoulders, and within calcified areas (Figure 1C) were
highly irregular, multilobular, and often, partially col-
lapsed. However, flattened and elongated but patent ves-
sels were also observed within lipidic cores (Figure 1-D2).
Analysis of CD105-positive vessels in coronary lesions obtained at 
transplant or following sudden death
There were fewer microvessels in intermediate and athero-
matous lesions than in advanced lesions. CD105 expres-
sion was strongest in the advanced lesions. CD105
immunostaining in the neovessels surrounding lipidic
cores of type III/IV lesions were positive. The majority of
neovessels were flattened and elongated (Figure 2A).
There was an increase in the number of CD105-positive
vessels in fibroatheromatous lesions. There were irregular
and multilobular vessels surrounding the lipidic core (Fig-
ure 3-A1 and 3A2). However, flattened and elongated but
patent CD105-positive vessels were also observed within
the lipidic core (Figure 3-A3). Within the shoulder differ-
ent vessel shapes were present: regular and circular vessels
and flattened, elongated but patent vessels (Figure 2-B1).
There were few inflammatory areas in complicated coro-
nary lesions. Flattened and elongated vessels were present
in these areas and in the shoulder (Figure 2-B2). Vessels
surrounding calcified lesions were unequivocally positive
for CD105. In general there were flattened and elongated
but patent vessels in these areas (Figure 3B). In these sam-
ples, the majority of the CD105-positive vessels were
immature with thin vessel walls and no evidence of
smooth muscle cell covering (Figure 3C black arrows).
More mature vessels stained weakly or negative for CD105
(Figure 3C, red arrows).
Middle cerebral arteries
Few CD105 positive neovessels were identified in intimal
lesions of these arteries. Only two cases of intermediate
lesions demonstrated angiogenesis. These neovessels were
small and elongated (Figure 4).
Representative positive CD105 immunostainig in carotid lesions Figure 1
Representative positive CD105 immunostainig in carotid lesions. A, neovessels within the lipidic core in a type III/IV 
plaque. B, An inflammatory area with multiple vessels in a fibroatheroma (arrows). C, Shows a calcified area with microvessels 
(arrows). D, Shows a fibroatheroma lesion; D1, surrounding lipidic core area; D2, area within the lipidic core. (Magnifications 
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Adventitial vasa vasorum concentration in plaque 
containing and plaque free regions
The median total microvessel count per square millimetre
in adventitia where there was visible intraluminal plaque
did not differ significantly with that of plaque free regions
in early or intermediate stage carotid arteries. However
there was a significant correlation between CD105-posi-
tive vasa vasorum in advanced plaque regions of coronary
arteries (p = 0.003). Results are presented in Table 4.
Discussion
In this study, we have identified significantly increased
CD105-positive microvessel density with increasing grade
of atherosclerotic lesion in carotid arteries with stenosis
<50% and in coronary arteries. Increased CD105-positive
intimal neovessels were demonstrated previously by Li et
al [18], whilst they also showed that CD105 staining was
almost absent in normal arteries. Since we previously
showed that cells (myoblasts) which do not normally
express CD105, when transfected with this gene, exhib-
ited increased cellular attachment, spreading, survival and
growth concomitant with increased phosphorylation of
JNK [15], and that CD105 expression is also up-regulated
by hypoxia and TGF-β, also features of plaque develop-
ment [22], the current observations suggest that CD105
expression is associated with active angiogenic neovascu-
larization in these lesions. In selected cases we compared
CD105 staining with CD34 positive vessels. There was less
CD105 positive vessels, further suggesting that this
marker is selective for active or new vessels.
There was a statistically significant increase in the maxi-
mum thickness of the neointima with increasing grade of
lesion in coronary, carotid and MCA arteries. This increase
correlated with an increase in the expression of CD105-
positive microvessels. The early stage (grade I-III) coro-
nary arteries generally contained stable uncomplicated
plaques with few areas of inflammation. This was in con-
trast to the larger calibre carotid arteries which exhibited
more complex heterogeneous features with more evi-
dence of inflammation and the presence of CD105-posi-
tive vessels in grade I-III + lesions. This adds more weight
to the evidence suggesting significantly different develop-
mental profiles between carotid and coronary artery dis-
eases with that of the carotid arteries demonstrating
higher angiogenic activity, possibly in part due to the
increased inflammatory infiltration and ultimately result-
ing in earlier production of unstable regions prone to
haemorrhage and rupture [1,12]. The prevalence of neo-
vascularization in carotid arteries of symptomatic patients
could help to explain the more rapid development of
unstable lesion and subsequent thrombosis. Further, we
know from the clinical experience that patients with low
to moderate carotid stenosis suffer strokes or transient
ischaemic attacks. These often are classified as of
unknown origin if screening for cardiac source of emboli
is negative and only non-significant intracranial or extrac-
ranial stenosis is detected [23,24]. Quickly evolving
carotid lesions without important lumen occlusion may
be at least partially responsible for these events.
In more advanced plaques (grade IV-V) there remained a
notable difference between coronary and carotid vessels
with respect to the numbers of neointimal CD105-posi-
tive microvessels and this was associated with larger inti-
mal thickness in the carotid arteries. There were no
notable differences in plaque CD105-positive vessel den-
sity in coronary or carotid arteries from patients who had
been undergoing treatment with antiplatelets and statins
and the others.
CD105 noevessel expression in representative coronary arterial plaques Figure 2
CD105 noevessel expression in representative coronary arterial plaques. A, neovessels surrounding the lipidic core 
in type III/IV lesions (arrows); B, more advanced lesions; B1, the shoulder area of the plaque; B2, internal inflammatory region 
(arrows). (Magnifications as specified within the Figures).Journal of Angiogenesis Research 2009, 1:6 http://www.jangiogenesis.com/content/1/1/6
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Atherosclerosis in the intracranial arteries is less studied,
although stenosis of MCA is a common cause of stroke in
some populations [25]. The exact frequency and role of
intracranial artery plaques in living patients with stroke is
still unknown in Caucassian population [26]. Intracranial
plaques and stenoses is highly prevalent in fatal stroke,
however, some of the reported stenoses graded 30% to
75% may be causal and correspond to superimposed clot
on ulcerated plaque. In our series MCA showed evidence
of intimal angiogenesis. This is in contrast to some of the
studies which reported higher prevelance of neovascula-
ture in plaques associated with stroke [25]. However, the
authors did not use any marker to show neovessels and
overall number of plaques with neovasculature was low.
Plaques developing in the intracranial arteries can proba-
bly survive and obtain nutrients by diffusion from the
existing adventitia. However the existence of CD105-pos-
itive vasa vasorum allows for the possibility that plaque
development still activates these vessels and that they are
affected by secretion of pro-angiogenic molecules from
the intimal site. It would be interesting to compare and
identify the mitogenic factors expressed in different vascu-
lar beds.
Our results indicate that intraplaque biomarkers, rather
than conventional risk factors, may reveal clinical and
radiological differences between patients with carotid and
MCA atherosclerosis. Plaques associated with MCA
atherosclerosis may be more stable than those associated
with carotid atherosclerosis [27].
CD105 noevessel expression in representative advanced coronary arterial plaques; A1, the area surrounding the lipidic core,  and A2, higher magnification showing an example of a multi-lobular abnormally formed neovessel (arrow); A3, shows an area  within the lipidic core (arrows) Figure 3
CD105 noevessel expression in representative advanced coronary arterial plaques; A1, the area surrounding the 
lipidic core, and A2, higher magnification showing an example of a multi-lobular abnormally formed neovessel (arrow); A3, 
shows an area within the lipidic core (arrows). B, shows a calcified area containing vessels (arrows). C, shows immature 
CD105-positively stained neointimal thin walled vessels (black arrows) adjacent to more mature thicker walled vessels 
expressing CD105 more weakly or not at all (red arrows). (Magnifications as specified within the Figures).Journal of Angiogenesis Research 2009, 1:6 http://www.jangiogenesis.com/content/1/1/6
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Perhaps surprisingly, there were no significant differences
between the numbers of CD105-positive vessels in the
adventitia adjacent to the plaque area compared with
non-plaque containing regions in carotid arteries. Since
the number of CD105-positive vessels was increased sig-
nificantly in all areas of the adventitia, it is possible that a
more general activation of the vasa vasorum occurs and
neointimal infiltrating endothelial cells are derived from
a more widespread region. This was demonstrated
recently by Coli et al [28], who showed that the number
of CD31/CD34 positive vasa vasorum microvessels corre-
lated with plaque echolucency, although not with the
degree of stenosis. In contrast, the numbers of vasa vaso-
rum CD105-positive vessels correlated strongly with areas
of plaque remodelling suggesting a more focussed process
of remodelling.
In the neointima we observed abnormal morphology in
many of the neovessels even in some of the early stage
grade II-III carotid lesions. Some of the vessels demon-
strated an elongated appearance but remained patent
whilst others were more irregular, multilobular and often
collapsed and non-functional. These immature vessels,
similar to those identified in growing tumours [29] are
more prone to rupture and haemorrhage. Dunmore et al
[3] showed that dilated, highly irregular multilobular ves-
sels were found almost exclusively in carotid plaques from
symptomatic patients and not in asymptomatic ones. The
vessels generally lacked smooth muscle cells, were imma-
ture and also existed in regions rich in VEGF-containing
macrophages. We also showed that the majority of
CD105-positive vessels were thin walled and immature
suggesting they were undergoing angiogenesis and/or
maturation associated with cellular activation.
Endoglin is a component of the TGFβ receptor complex
expressed mainly on the surface of endothelial cells. TGFβ
has notable effects on cell proliferation, differentiation,
adhesion, migration, and extracellular matrix production,
as well as other activities [30]. Endoglin binds to members
of the TGFβ superfamily and modulates cellular responses
to TGF-β1. The growth factor TGF-β1 is involved in the
pathogenesis of atherosclerosis through its pleiotropic
effects [31]. Some reports show anti-atherogenic proper-
ties to TGF-β1 [32,33], whereas others show that it has
atherogenic properties [34,35]. Piao et al found an
increased expression of TGF-β1 in atherosclerotic lesions
and an especially strong over-expression and higher
expression rate in the advanced lesions, suggesting that
TGF-β1 participates in the formation of early lesions and
the progression to advanced lesions [22]. CD105 may ini-
tiate its effects in atherosclerosis at an early stage through
interaction with TGFβ, but we do not know if the expres-
sion of these proteins is causative or a result of the athero-
genesis.
It could be useful in a therapeutic setting to differentiate
perhaps with specific markers and imaging, patent func-
tional and stable vessels from mal-formed, leaky and
unstable ones liable to haemorrhage. Future treatment
aimed at stabilization of immature vessels could help in
the control of developing lesions.
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